Stem Cell Induction via HMBPP Phosphate Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing stem cells with a rearranged γδ-TCR gene are inefficient, particularly in obtaining sufficient numbers of TCRγδ-type T cells for cancer immunotherapy.
Innovation Solution
A method involving the application of a phosphate, such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, to blood cells, combined with the introduction of an inducer RNA and the use of a Sendai virus vector, to efficiently induce stem cells with a rearranged γδ-TCR gene.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zoledronic acid is used to initialize blood cells and induce iPS cells with γδ-TCR gene, then stem cells can be obtained, but the γδ-TCR gene rearrangement is incomplete (J1/J2 gene has not undergone rearrangement)
Solution Approach 1:
The patent changes the chemical parameter by replacing zoledronic acid with HMBPP, which is an intermediate product in the non-mevalonate pathway. This parameter change resolves the contradiction by achieving both complete γδ-TCR gene rearrangement (including J1/J2 genes) and maintaining high stem cell induction efficiency, as demonstrated in the examples where HMBPP treatment resulted in successful rearrangement unlike zoledronic acid.
2Quantity of substance
If TCRγδ-type T cells are obtained from peripheral blood, then cancer immunotherapy can be performed, but sufficient T cells cannot be obtained due to low abundance (1% to 5% in peripheral blood)
Solution Approach 1:
The patent applies preliminary action by treating blood cells with HMBPP before inducing iPS cells, which pre-activates the γδ-TCR gene rearrangement process. This preliminary treatment ensures that when stem cells are induced and subsequently differentiated into T cells, sufficient numbers of TCRγδ-type T cells with complete rearrangement are obtained, overcoming the low abundance problem in peripheral blood.
3Quantity of substance
If blood collection is carried out to obtain TCRγδ-type T cells, then material for therapy can be acquired, but insufficient cells are obtained due to low frequency in blood
Solution Approach 1:
By applying HMBPP to blood cells before iPS cell induction, the patent performs a preliminary activation step that ensures complete γδ-TCR gene rearrangement. This preliminary action increases the productivity of therapy material production by ensuring that the induced stem cells will differentiate into sufficient numbers of functional TCRγδ-type T cells with complete rearrangement, making the overall process more efficient despite starting from low-abundance cells.
Data Source
AI summary
According to the present disclosure, there is provided a method for producing stem cells, which includes applying a phosphate to blood cells and inducing stem cells from the blood cells. The phosphate may be an intermediate product or a final product in a non-mevalonate pathway. The phosphate may be (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate.